HHS Overhauls Grants Policy, CDC Faces Budget Cuts, and Regulatory Changes Ahead

The big headline from the Department of Health and Human Services this week is the release of sweeping changes in grants policy—updates that signal one of the most significant overhauls for funding recipients in years. Starting October 1st, the new HHS Grants Policy Statement aligns all HHS grants with federal Uniform Guidance. This means new rules for grantees, from tighter civil rights assurances to stricter budget revision thresholds—now requiring prior approval for changes above 10% of the total grant, down from the previous 25%. HHS now claims the right to terminate awards for its own convenience, with no appeal, shaking up how organizations plan for long-term projects. Ted Waters of Feldesman Tucker described the policy as “the biggest compliance shift grantees have faced since the first Uniform Guidance.” On the legislative front, the House Appropriations Committee advanced the 2026 funding bill for HHS, proposing $108 billion—about 7 billion dollars less than last year and notably less than the Senate’s proposal. While the bill preserves funding for crucial mRNA vaccine research, it stops new CMS pilot programs like the controversial WISeR AI-driven Medicare fraud reduction and aims to block further mandates like nursing staff minimums at long-term care facilities. Meanwhile, the CDC faces a proposed 19 percent budget cut, the sharpest in recent memory. These political battles directly impact the resources available to hospitals, clinics, and researchers, as well as future public health readiness. In regulatory news, the FDA initiated heightened enforcement on pharmaceutical advertising, sending 100 cease-and-desist letters to companies for deceptive direct-to-consumer ads and launching rulemaking to close loopholes in advertising regulations. This move aims to address concerns over misleading drug marketing and to increase accountability in the industry—a campaign HHS Secretary Robert Kennedy Jr. described as part of a broader “radical transparency” initiative. Organizational changes are also underway as HHS moves ahead with its 2025 reorganization, which consolidates five agencies into a new Administration for a Healthy America and restructures the CDC towards infectious diseases. About 20,000 jobs across HHS—most from the FDA and CDC—will be eliminated or realigned, potentially affecting response capacity to both ongoing and emerging health threats. Policy shifts continue to reverberate beyond Washington. HHS recently expanded restrictions on federal health and social programs, barring many lawfully present as well as undocumented immigrants from vital services like Head Start, family planning, and behavioral health programs. Advocacy groups warn this could increase pressure on hospitals, states, and localities, especially in regions serving diverse communities. Public health alerts remain steady, with the CDC’s Immunization Practices Committee meeting this week to vote on new recommendations for measles, hepatitis B, and COVID-19 This content was created in partnership and with the help of Artificial Intelligence AI.